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WHAT THIS PAPER ADDS?
 Currently, endovascular treatment of long femoropopliteal lesions as a ﬁrst-choice treatment remains controversial. Despite a high
technical success rate, little data are available on the clinical beneﬁt for patients over time. In the present study we prospectively
assessed the safety and the efﬁcacy of primary stenting for TASC C and D femoropopliteal lesions. We found that sustained clinical
improvement at mid-termwas high. Nevertheless, the necessity of secondary procedures due to in-stent restenosis and thrombosis
makes narrow surveillance mandatory. Therefore, our results contribute to further support the use of primary stenting for TASC C
and D femoropopliteal lesions.a r t i c l e i n f o
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Objective: The study aims to evaluate the safety and the efﬁcacy of primary stenting for Trans-Atlantic
Inter-Society Consensus Document II on Management of Peripheral Arterial Disease (TASC) C and D
femoropopliteal lesions.
Design: Prospective cohort study.
Methods: Patients with TASC C and D de novo femoropopliteal lesions were treated with the same
endovascular technique by implanting a primary nitinol self-expanding stent (LifeStent, Bard Peripheral
Vascular, Tempe, AZ, USA). Patients were included in a single-centre registry and prospectively followed
up. The primary end point was primary sustained clinical improvement after 12 months. Secondary end
points were secondary sustained clinical improvement, primary and secondary patency rates, freedom
from target lesion revascularisation (TLR), freedom from target extremity revascularisation (TER) and
stent fracture rate.
Results: We enrolled 58 patients (62 limbs) suffering from either claudication (40.3%) or critical limb
ischaemia (59.7%). Lesions were either TASC C (62.9%) or TASC D (37.1%). Median length of the treated
segment was 220  160 mm. The mean number of stents was 2.2. Mean follow-up was 17 months, with
one patient lost to follow-up. At 1 year, the primary end point was 68.6% while secondary sustained
clinical improvement was 82.6%. Freedom from TLR and TER rates were 81.1% and 96.3%. Primary and
secondary patencies were 66% and 80.9%. One-year primary and secondary sustained clinical improve-
ment rates were 76.7%  7.2 for TASC C and 46.3%  11.1 for TASC D (p ¼ 0.03) and 87.6%  5.9 for TASC C
and 67.3%  11.3 for TASC D (p ¼ 0.09), respectively. The ankleebrachial pressure index increased fromcal limb ischaemia; DSA, digital subtraction angiography; IC, intermittent claudication; ISR, in-stent restenosis; MACE,
l disease; PSV, peak systolic velocity; TASC, Trans-Atlantic Inter-Society Consensus Document II on Management of
ascularisation; TLR, target lesion revascularisation.
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J.-M. Davaine et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 432e441 4330.58 to 0.94 (p ¼ 0.001) at 1 year and the incidence of in-stent restenosis (ISR) was 19.3%. Stent fracture
and disconnection rate was 17.7%.
Conclusions: Primary stenting of TASC C and D lesions appears to be safe and efﬁcient given the high-
sustained clinical improvement and the low rate of ISR observed in our study. Endovascular treatment
of such long and severe lesions exposes to high rate of stent fractures, which should not be a concern
given their low clinical impact.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
 Age  50-years
 Symtomatic patients according
Rutherford stages 3, 4, 5 and 6
 De novo atheromatous femoropopliteal
occlusive disease >15 cm in length
 TASC CeD femoro-popliteal lesions
according the TASC II guidelines
 Adequate femoro-popliteal inﬂow
and outﬂow either pre-existing or
successfully re-established (outﬂow
deﬁned as patency of at least one
infragenicular artery)
 Successful crossing of the target
lesion, inﬂow and outﬂow lesions
with a guide wire
 Written informed consent
 Patient belongs to the French
health care system
 Restenosis
 No atheromatous disease
 Asymptomatic lesion
 Acute ischaemia or arterial
thrombosis
 Lesion within or adjacent to
an aneurysm
 Patient enrolled in another trial
 Refusing patient
 Pregnancy
 Known allergies to heparin,
aspirin, other anti-coagulant/
antiplatelet therapies
 No written informed consent
 Life expectancy < 1 yearThe Trans-Atlantic Inter-Society Consensus Document II on
Management of Peripheral Arterial Disease (TASC) was published in
2007.1 In its revised stratiﬁcation for femoropopliteal lesions, TASC
II included more severe disease levels than TASC I and recom-
mended endovascular repair for type A, B and C (with qualiﬁca-
tions). However, endovascular repair remains commonly indicated
in limited lesions shorter than 150 cm whereas bypass surgery is
recommended to treat extensive disease with long lesions and
critical limb ischaemia (CLI).
Recent advances in endovascular techniques have led to wide-
spread applicability of endovascular repair for more severe femo-
ropopliteal lesions. Even though lesions are more distal and longer,
the technical success does not seem to be altered. Successful
recanalisation of TASC C and D lesions exceeds 80%.2,3 In addition,
the use of new techniques and devices such as retrograde approach
and re-entry catheters improves the technical success rates
following failed initial procedure.2 According to some authors,
failure of endovascular repair does not preclude the possibility of
infrainguinal bypass.4 Thus, the use of primary stenting to treat
femoropopliteal occlusive lesions has shown the most promising
outcomes.5 However, primary stenting for longer femoropopliteal
lesions is controversial because of the high risk of stent fracture.
Newer generations of longer nitinol self-expanding stents could
allow endovascular treatment of longer femoropopliteal lesions
thanks to their resistance to compression and fracture in this
tortuous physical environment.6 The purpose of the Stenting long
de l’artère fémorale superﬁcielle (STELLA) study was to evaluate
prospectively the safety and the efﬁcacy of primary stenting using
LifeStent (Bard Peripheral Vascular, Tempe, AZ, USA) to treat
femoropopliteal TASC C and D lesions.
Methods
Experimental design
STELLA is a follow-up single-centre study cohort in which
patients were referred for peripheral arterial disease (PAD) and
presented with de novo femoropopliteal TASC C and D lesions
longer than 15 cm. Patients were enrolled between November 2008
and October 2009. Endovascular therapy was considered a ﬁrst
intention treatment. Inclusion and exclusion criteria are summar-
ised in Table 1. Patients had either one or two limbs treated. The
protocol was approved by the local ethics committee and all
patients gave informed consent.
Endovascular procedures
All procedures were performed by vascular surgeons. Patients
were examined preoperatively by an anaesthesiologist. Local
anaesthesia with conscious sedation was indicated unless general
anaesthesia was required. Access to the culprit lesion was achieved
either by way of an over-the-aortic-bifurcation approach with the
use of a dedicated 6F-long sheath (45 cm) (Destination, Terumo, St
Quentin, France) or via antegrade approach with the use of a 6F
sheath (Destination, Terumo, St Quentin, France). After sheathplacement, an intravenous bolus of 50 UI kg1 of heparin was
administered. Stenotic lesions were crossed in an intraluminal
fashion and occlusions were recanalised with a hydrophilic 0.035-
inch guide wire and a balloon catheter (Optapro, Cordis, Issy,
France). An intentional plane was created in the proximal patent
artery by forming a loop at the end of the guide wire. The looped
guide wire and the balloon catheter were then forcefully advanced
across the occlusion. The true lumen re-entry was indicated by
a subtle release of wire resistance near the distal portion of arterial
occlusion. Distal re-entry was ensured after withdrawal of the
guide wire by contrast media injection through the balloon lumen
catheter. No re-entry device was used. Primary stenting was pref-
erably performed unless predilation with a 3-mm balloon was
necessary because of highly calciﬁed lesions. The stent dimensions
were chosen by visual estimation to ﬁt vessel diameter at best with
a length exceeding the lesion length by 5e10 mm proximally and
distally. The maximal available length of stent was 170mm. Lesions
were treated with as few stents as possible. Adjacent stents over-
lapped by 1 cm. We used the self-expandable LifeStents (Bard
Peripheral Vascular, Tempe, AZ, USA) of either 6 or 7 mm in
diameter. Stents were routinely post-dilated to ensure optimal
extension and apposition. The balloon dimension (Optapro, Cor-
dis, Issy, France) was chosen so that the nominal diameter is 1 mm
narrower than the vessel diameter to reduce medial damage7 and
so that the balloon length does not exceed that of the stent. The
technical result of the procedure was assessed by digital subtrac-
tion angiography (DSA). Every associated inﬂow or outﬂow lesions
suspected to be involved in the disease were treated during the
same procedure. Signiﬁcant aspect of the lesionwas assessed by the
surgical team according to preoperative ﬁndings (magnetic reso-
nance imaging (MRI), angio-computed tomography (CT) scan and
duplex ultrasonography (US)), clinical stage of the disease (CLI vs.
intermittent claudication (IC)) as well as to intra-operative ﬁndings
(DSA). Groin closure was accomplished via manual compression
Table 2
Baseline patients characteristics.
Variables
Age, yr (mean  SD) 71.4  12
Male sex, n (%) 42 (72.4)
Smoking, n (%) 34 (58.6)
Active 13 (22.4)
Previous 21 (36.2)
Hypertension, n (%) 48 (82.8)
Hyperlipidaemia, n (%) 29 (50)
Diabetes mellitus, n (%) 25 (43.1)
Type I 2 (3.4)
Type II 23 (39.7)
Renal insufﬁciency 13 (22.4)
On dialysis 1 (1.7)
Obesity (BMI > 25), n (%) 27 (46.6)
Coronary artery disease, n (%) 28 (48.3)
Cerebrovascular disease, n (%) 9 (15.5)
Rutherford stage of PAD, n (%)
3 25 (40.3)
4 13 (21)
5 20 (32.2)
6 4 (6.5)
Clinical status
Claudication, n (%) 25 (40.3)
Critical limb ischaemia, n (%) 37 (59.7)
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(Angioseal, St Jude Medical, France).
A prophylactic dose of low-molecular-weight heparin was given
during hospitalisation to prevent venous thrombo-embolic events.
Postoperatively, patientswereprescribed aspirin (75e160mgday1)
and clopidogrel (75 mg day1) for 6 months and then patients were
prescribed only clopidogrel.5,8 When patients were under oral anti-
coagulant treatment, aspirinwas the only anti-platelet agent added.
Observance to themedical treatmentwas ascertained at each clinical
end point.
Follow-up
Patients were prospectively followed on an outpatient basis.
Major adverse clinical events (MACEs) were intentionally sought.
Follow-up included medical examination, ankleebrachial index
(ABI) measurement and duplex scan at 1, 3, 6, 9, 12 and 18 months
and yearly thereafter. Information collected on standardised forms
ﬁlled during Doppler US examination was systematically ascer-
tained by a surgeon in charge of the study. For this purpose, patients
and general practitionerswere contacted by telephone. The hospital
database was systematically searched for any additional relevant
information. Clinical examinationwas performed by the surgeon at
1 and 12 months postoperatively. Stent fractures were assessed by
biplane X-rays at 12 months with two different projections sepa-
rated by at least 45 using the highest available magniﬁcation. Data
were recorded prospectively in a computerised database. Logistic
organisation was provided by two clinical research ofﬁcers. An
independent core laboratory (CoreLab, Bad Krozingen, Germany)
analysed X-rays for stent fractures. Magniﬁcation of the images was
used in any case in which stent strut fracture was suspected using
the QVA software (Medis medical imaging systems, Leiden, the
Netherlands). Stent fracture was ﬁnally assessed by a medical
advisor according to the Jaff classiﬁcation.9
End points and deﬁnitions10
The primary end point was primary sustained clinical
improvement at 12 months.
Secondary end points were secondary sustained clinical
improvement, primary and secondary patency, technical success,
minor and major complications, major cardiovascular events
(MACEs), limb salvage, target lesion revascularisation (TLR), target
extremity revascularisation (TER), in-stent restenosis (ISR), in-stent
thrombosis and stent fracture. Detailed deﬁnitions of outcome are:
Primary sustained clinical improvement was deﬁned as a sus-
tained upward shift of 1 category of the Rutherford classiﬁcation
for claudicants and by wound healing and rest pain resolution for
patients in CLI, without the need for repeated TLR in surviving
patients. Secondary sustained clinical improvement was deﬁned as
primary sustained clinical improvement including the need for
repeated TLR. Primary patency was deﬁned as patency without any
percutaneous or surgical intervention in the treated segment or in
the adjacent areas. Technical success was deﬁned as achievement of
a ﬁnal residual diameter stenosis of <30% on the procedural
completion angiogram. Minor complications are those following
procedure (within the ﬁrst month) and not requiring further
treatment and not extending hospital stay. Major complications
required re-intervention or delay (more than 24 h) in patient
discharge. MACE included all deaths, major amputation,
procedural-related serious adverse events and device failure or
malfunction. TLR expresses the frequency of the need for repeated
procedures (endovascular or surgical) due to a problem arising
from the lesion (þ1 cm proximally and distally to include edge
phenomena) in surviving patients with preserved limb. TERexpressed the frequency of the need for repeated procedures due to
a problem arising remotely from the initial lesion. ISR were
assessed by duplex ultrasound and was deﬁned by restenosis of
more than 50% and by a peak systolic velocity (PSV) index greater
than 2.4 at the lesion site. The diagnosis of stent thrombosis was
considered when occlusion was seen on duplex scan without any
previous sign of restenosis. The occurrence of stent fracture was
determined by biplane radiography at 12 months.9
Statistical analysis
Statistical analysis results were reported prospectively on an
intention-to-treat basis. Continuous variables were presented as
mean  SD, categorical variables as count and percent. Demo-
graphic and co-morbidity data were recorded per patient and
patency data were calculated on a per limb basis. Survival rate
curves for TLR/TER were plotted and calculated using the
KaplaneMeier method. For patients who died before the ﬁnal
follow-up examination or for patients lost to follow-up, the status
of the last follow-up examination was recorded. A p-value <0.05
was considered statistically signiﬁcant. Data were analysed using
the Statistical Package for the Social Sciences (SPSS) software (SPSS
Inc., Chicago, IL, USA).
Results
Patients’ characteristics and demographics
A total of 58 patients (62 limbs) were enrolled. Over the same
period, 302 patients were treated for femoropopliteal lesions
(endovascular repair: 231; open repair: 71). The baseline charac-
teristics of the study population are described in Table 2. Indica-
tions for intervention included 25 limbs (40.3%) for claudication
and 37 limbs (59.7%) for CLI.
Intra-operative and perioperative data
Details of the 62 endovascular procedures are given in Table 3.
According to the TASC II classiﬁcation, 39 limbs (62.9%) were clas-
siﬁed as TASC C and 23 limbs (37.1%) as TASC D. The over-the-
bifurcation approach was realised for 38 limbs (61.3%) and an
Table 3
Baseline intraoperative and perioperative data.
Variables
TASC II classiﬁcation of the lesions, n (%)
C 39 (62.9)
D 23 (37.1)
Approach, n (%)
Crossover 38 (61.3)
Antegrade 24 (38.7)
Length of the treated lesions, mm (median, IQR) 220 mm  160 mm
Length of stented segment, mm (median, IQR) 260 mm  180 mm
Number of stent per patient, n (mean  SD) 2.2  0.9
Number of stents implanted, n (%) 134 (100)
1 16 (25.8)
2 22 (35.5)
3 22 (35.5)
4 2 (3.2)
Diameter of implanted stent, n (%) 134 (100)
6-mm 104 (77.6)
7-mm 30 (22.4)
Crural runoff vessels (ultrasound), n (%)
1 12 (19.4)
2 18 (29)
3 14 (22.6)
Not documented 18 (29)
Associated procedures, n (%)
Endovascular repair 20 (32.2)
Aortic bifurcation 1 (1.6)
Common iliac artery 1 (1.6)
External iliac artery 6 (9.7)
Internal iliac artery 2 (3.2)
Common femoral artery 2 (3.2)
Below the knee arteries 7 (11.3)
Controlateral iliac artery 1 (1.6)
Open repair 4 (6.4)
Femoral edarteriectomy 3 (4.8)
Controlateral femoro-popliteal bypass 1 (1.6)
Minor amputations 3 (4.8)
Major amputations 0 (0)
Major adverse cardiovascular event, n (%) 2 (3.4)
Day-case vascular procedure, n (%) 5 (8.1)
Duration of ﬂuoroscopyin, min (mean  SD) 18.9  10
Irradiation, mGy/m2 (mean  SD) 3.3  3
Duration of procedure, min (mean  SD) 79  36
Amount of contrast agent, ml (mean  SD) 87  36
Duration of hospital stay, d (mean  SD) 3  4
Perioperative complications, n (%)
Minor 5 (8.1)
Major 6 (9.7)
TASC: Trans-Atlantic Inter-Society Consensus.
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treated lesions was 220  160 mm (150e480 mm). Forty-eight out
of the 62 (77.4%) of the lesions involved the popliteal artery. Median
stented segment was 260  180 mm and the mean number of
stents implanted per limbs was 2.2  0.9 (1e4). In 77.6% of the
cases, 6-mm diameter stents were implanted. Concomitant treat-
ment was performed for 20 limbs (32.2%) by endovascular repair
and for four limbs (6.4%) by open repair. During the perioperative
period, no patient was lost to follow-up. One patient died within 1
month after the procedure from congestive heart failure. Six (9.7%)
major complications led to an extent of hospitalisation and/or re-
intervention e two puncture site haematomas, one post-revascu-
larisation syndrome, one acute coronary syndrome, one congestive
heart failure and one bowel obstructive syndrome. Three minor
amputations (4.8%) were required but no major amputation. The
average length of hospitalisation stay was 3 days (1e25). Five limbs
(8.1%) were treated in the context of day-case vascular procedure.
In these cases, an arterial femoral closure device (angioseal 6F, St
Jude Medical, France) was used to allow early discharge. Detailed
information regarding both TASC and clinical status is given in
Table 4. Patients presenting with CLI were older than patientspresenting with claudication (p ¼ 0.004) and were more frequently
females (p ¼ 0.04). The number of stents implanted, lesion and
stenting lengths were higher in TASC D compared with TASC C
patients (p ¼ 0.0001). The procedure was also longer in TASC D vs.
TASC C patients (p ¼ 0.003).
Follow-up
Themean follow-up time (Table 5) was 17.2 months (1e30). One
patient was lost to follow-up (follow-up time: 9th month). Five
(8.0%) patients died during the follow-up period (one within 30
days and four within 1 year) (Table 5).
At 1 month, the clinical status was improved in 55 limbs and the
primary sustained clinical improvement was 90.1  2.2%. Six limbs
did not improve and one remained unchanged. Five patients with
CLI did not heal satisfactorily and were considered not improved.
One-month primary sustained clinical improvement rates were
100% for TASC C, 95.5% 4.4 for TASC D,100% for IC and 97.3% 2.7
for CLI, respectively. One-month secondary sustained clinical
improvement rates were 100% for TASC C, 95.5%  4.4 for TASC D,
100% for IC and 97.3%  2.7 for CLI, respectively (Table 6). At 1 year,
primary and secondary sustained clinical improvement was ob-
tained in 37 (68.6%  6) and 48 (82.6%  5.1) limbs, respectively
(Fig. 1). No patient developed clinical worsening compared to
baseline. Thirty-ﬁve (64.8%) limbs were considered asymptomatic,
claudication and CLI were observed in 16 (29.6%) and in three (5.6%)
cases, respectively (Fig. 2). No improvement was achieved in six
(11.1%) limbs. One-year primary sustained clinical improvement
rates were 76.7% 7.2 for TASC C, 46.3% 11.1 for TASC D (p¼ 0.03),
74.1%  1.0 for IC and 60.1%  8.3 for CLI (p ¼ 0.23), respectively.
One-year secondary sustained clinical improvement rates were
87.6% 5.9 for TASC C, 67.3%  11.3 for TASC D (p¼ 0.09), 84%  8.5
for IC and 77.7% 7.5 for CLI (p¼ 0.54), respectively (Table 6). Mean
Rutherford index at baseline and at 12 months were 4.1  1.0 and
0.8  1.3, respectively (p < 0.001) (Fig. 2). There was no limb loss in
claudicants. The limb salvage rate at 1 year in patients with CLI was
97.3%. One patient, despite patent stent, required major amputa-
tion. Complete wound healing was achieved in 17 out of the 24
cases after 1 year. Additional procedures were necessary in two
cases (one TER and one TLR).
Mean ABI increased from baseline levels of 0.59  0.1 to
0.94 0.2 at 1 month and remained elevated at 0.94  0.2 at 1 year
(p < 0.001) (Fig. 3).
At 1 year, primary and secondary patency rates were 66% and
80.9%, respectively (Fig. 4). One-year primary patency rates were
82.1%  6.6 for TASC C, 44%  11.4 for TASC D (p ¼ 0.009),
79.4%  9.2 for IC and 61.4%  8.4 for CLI (p ¼ 0.17), respectively.
One-year secondary patency rates were 84.9%  6.2 for TASC C,
63.9% 12.4 for TASC D (p¼ 0.12), 90% 6.7 for IC and 71% 8.3 for
CLI (p ¼ 0.15), respectively (Table 6). During follow-up, seven
(11.3%) cases of stent thrombosis and 12 (19.3%) cases of ISR were
observed. Patients with TASC D lesions displayed a higher rate of
ISR comparedwith TASC C patients (35% vs. 10%, p¼ 0.005, Table 4).
Of the seven cases of stent thrombosis, one occurred within 30
days, none occurred within 31 days to 3 months, three occurred
within 3e6 months and three occurred within 6e12-months.
Among seven patients with stent thrombosis, two patients under-
went palliative treatment due to severe and life-threatening co-
morbidities, three patients underwent a walking programme in the
absence of CLI and the last two patients underwent a re-
intervention (one femoropopliteal bypass and one angioplasty)
since they presented with CLI. Of the 12 (19.3%) cases of ISR, none
occurred within 30 days, three occurred within 31 days to 3
months, ﬁve occurred within 3e6months and four occurred within
6e12 months. Of the 12 cases of ISR, six patients presented with
Table 4
Main characteristics (demographic, clinical, procedural) according to TASC classiﬁcation of lesions and clinical presentation of patients.
TASC C TASC D p value IC CLI p value
Age (mean  SD) 72  10 68  15 0.215 66  10 74  12 0.004
Male, Nb (%) 27 (69) 19 (83) 0.25 22 (88) 24 (65) 0.04
IC, Nb (%) 18 (46) 7 (30) 0.22 25 (100) 0 (0) e
CLI, Nb (%) 21 (54) 16 (70) 0.22 0 (0) 37 (100) e
TASC C, Nb (%) 39 (100) 0 (0) e 18 (72) 21 (57) 0.22
TASC D, Nb (%) 0 (0) 23 (39) e 7 (28) 16 (43) 0.22
Ruth. (baseline) 4  1 4  1 0.31 3  0 5  1 0.0001
Ruth. (1st month) 1  2 2  2 0.061 1  1 2  2 0.001
Ruth. (12th month) 1  1 1  1 0.459 1  1 1  1 0.375
ABI (baseline) 0.5  0.1 0.60  0.1 0.054 0.6  0.1 0.6  0.1 0.112
ABI (1st month) 1  0.2 0.9  0.2 0.335 1  0.2 0.9  0.2 0.316
ABI (12th month) 1  0.2 0.9  0.2 0.028 1  0.2 1  0.2 0.529
Nb of stent, (mean  SD) 2  1 3  1 0.0001 2  1 2  1 0.06
Lesion length, (mean  SD) 183  60 334  79 0.0001 216.49  1 254  98 0.146
Stenting length, (mean  SD) 213  67 366  79 0.0001 237  96 289  103 0.135
Associated angioplasty, Nb (%) 10 (26) 10 (43) 0.15 7 (28) 13 (35) 0.55
Associated surgery, Nb (%) 4 (10) 0 (0) 0.09 0 (0) 4 (11) 0.32
Contrast agent, ml (mean  SD) 82  39 96  29 0.162 97  42 80  29 0.095
Irradiation, (mGy/m2) 2.96  3.12 4.07  2.6 0.208 4.17  3.34 3.71  2.58 0.079
Procedure length, min (mean  SD) 69  30 97  39 0.003 78  43 80  31 0.845
Hospital stay, days (mean  SD) 3  4 3  4 0.601 2  3 4  3 0.064
Minor complications, Nb (%) 3 (8) 4 (17) 0.51 2 (8) 5 (14) 0.81
Major complications, Nb (%) 2 (5) 4 (17) 0.18 2 (8) 4 (11) 0.99
ISR, Nb (%) 4 (10) 8 (35) 0.005 4 (16) 8 (22) 0.44
Thrombosis, Nb (%) 4 (10) 3 (13) 0.62 1 (4) 6 (16) 0.19
TLR, Nb (%) 5 (13) 6 (26) 0.23 3 (12) 8 (22) 0.45
TER, Nb (%) 2 (5) 0 (0) 0.36 0 (0) 2 (5) 0.23
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tomatic. Symptomatic patients were treated. Asymptomatic ISR
were considered to threaten vessel patency in three cases (for the
three other asymptomatic ISR, surveillance was recommended). A
total of nine redo procedures were performed. These procedures
consisted of redo angioplasty in all cases but one, in which a veinTable 5
Outcomes of the patients.
Variables
Death, n (%) 5 (8.5)
Massive cardiac failure (on day 2) 1 (1.7)
Cerebrovascular accident (3rd month) 1 (1.7)
Myelodysplasia acutisation (3rd month) 1 (1.7)
Pulmonary neoplasia (6th month) 1 (1.7)
Unknown (11th month) 1 (1.7)
Major adverse cardiovascular event, n (%) 4 (6.8)
Pulmonary oedema(3rd month) 1 (1.7)
ACBG (6th month) 1 (1.7)
ACS (6th month) 1 (1.7)
PMK implantation (6th month) 1 (1.7)
Amputations, n (%) 1 (1.7)
Minor 0 (0)
Major 1 (1.7)
Wound healing, n (%) 17 (70.8)
Infection, n (%) 2 (3.2)
Digestive bleeding, n (%) 1 (1.7)
Intrastent restenosis, n (%) 12 (19.3)
1st month 0 (0)
3rd month 3 (4.8)
6th month 5 (8.1)
9th month 2 (3.2)
12th month 2 (3.2)
Stent thrombosis, n (%) 7 (11.3)
1st month 1 (1.6)
3rd month 0 (0)
6th month 3 (4.9)
9th month 1 (1.6)
12th month 2 (3.2)
ACBG: acute coronary bypass grafting, ACS: acute coronary
syndrome, PMK: pace maker.femoropopliteal bypass was performed. All patients, but two, were
clinically improved at 12 months. These two patients were clau-
dicants and a conservative treatment was chosen.
At 1 year, TLR and TER-free cumulative survival rates were
80.3  5.3% and 96.5  2.4%, respectively (Fig. 5(a) and (b)). A total
of 11 TLR and two TER were performed during follow-up. Of the 11
TLR procedures, endovascular repair was performed in nine cases
to treat ISR (n ¼ 8) and in one case to treat in-stent thrombosis
(n¼ 1). Surgical repair was realised to treat one ISR and one in-stent
thrombosis. The two TER procedures were angioplasties performed
to maintain vessel patency.
The survey of medical treatment is represented in Table 7. All
patients received at least one anti-platelet agent for the ﬁrst 6
months and 67% of them were on both aspirin and clopidogrel.
Occurrence of in-stent thrombosis was observed in ﬁve patients
taking two anti-platelet agents, and in two patients taking only one
anti-platelet agent.
Complete X-ray follow up was obtained for 42 treated limbs.
Ninety stents were analysed and 16 fractures were noted (17.7%).
We observed one type I, seven type II, ﬁve type III and three type IV
fractures. Loss of primary patency was associated with six cases ofTable 6
Primary and secondary sustained clinical improvement and patency according to
TASC classiﬁcation and clinical presentation (IC vs. CLI).
TASC C TASC D p IC CLI p
Primary sustained clinical improvement, % SD
1 month 100 95.5  4.4 100 97.3  2.7
12 months 76.7  7.2 46.3  11.1 0.03 74.1  1.0 60.1  8.3 0.23
Secondary sustained clinical improvement, % SD
1 month 100 95.5  4.4 100 97.3  2.7
12 months 87.6  5.9 67.3  11.3 0.09 84  8.5 77.7  7.5 0.54
Primary patency, % SD
1 month 100 100 100 100
12 months 82.1  6.6 44  11.4 0.009 79.4  9.2 61.4  8.4 0.17
Secondary patency, % SD
1 month 100 100 100 100
12 months 84.9  6.2 63.9  12.4 0.12 90  6.7 71  8.3 0.15
Figure 1. Primary and secondary sustained clinical improvement. One year primary and secondary sustained clinical improvement rates were 68.6% and 82.6%, respectively.
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with one case of stent fracture (type IV). Occurrence of ISR was
related to ﬁve cases of stent fractures. Clinical impact and
management of stent fractures are reported in Table 8.Discussion
In this single-centre cohort, we have evaluated prospectively the
safety and the efﬁcacy of primary stenting using LifeStent (Bard
Peripheral Vascular, Tempe, AZ, USA) to treat TASC C and D femo-
ropopliteal lesions. Most of the procedures were performed to treat
patients presenting with CLI. This strategy offered acceptable initialFigure 2. Clinical outcomes up to 12 months. At one year 35 (64.8%) limbs were
asymptomatic, 16 (29.6%) presented with IC and 3 (5.6%) with CLI compared with 60%
of patients presenting with CLI and 40% with IC at baseline. (R0 to R6: Rutherford stage
0 to Rutherford stage 6).results at 1 year with high-sustained clinical improvements and
low rate of re-intervention despite an elevated percentage of stent
fracture.
Despite the absence of recommendations, primary stent
implantation for TASC C and D femoropopliteal lesions has become
routine practice. For instance, many manufacturers offer stents
longer than 15 cm and up to 20 cm. However, evidence is lacking
concerning the clinical outcome of such treatment. In our study, we
observed that the rate of patients presenting with CLI was 60%Figure 3. Sustained haemodynamic improvement at 1 year. Mean ankle brachial index
increased from baseline levels of 0.59  0.1 to 0.94  0.2 at 1-month and 0.94  0.2 at
1-year (p < 0.001). ABI: ankle brachial index; CI: conﬁdence interval.
Figure 4. Primary and secondary patency. One-year primary and secondary patency rates were 66% and 80.9%, respectively.
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of CLI patients were reported.5,11 Others have recently investigated
the results with primary stenting in femoropopliteal lesions longer
than 15 cm.12 The mean lesion length was 242 mm, lesions
extended to the popliteal artery in 27% of the cases and the rate of
CLI was 29%. By contrast, the popliteal artery was involved in 77.4%
of our patients. This high rate of popliteal artery involvement could
explain the differences in CLI rates between both studies since
lesions extending to the popliteal arterymay preclude the collateral
circulation from the deep femoral artery.
Clinical improvement
After 1-year follow-up, primary sustained clinical improvement
was 68.6% while secondary sustained clinical improvement was
82.6%. No patient has experienced clinical worsening following
endovascular procedure. Six percent of our patients presented with
CLI at 1 year vs. 59.7% at baseline. Only one patient required major
amputation. Clinical improvement was also correlated with a hae-
modynamic parameter since mean ABI was normalised at 1 year. In
two cases, a femoropopliteal bypass was realised during follow-up
with no difﬁculty related to prior endovascular procedure. In
contrast to our ﬁndings as well as those of Bosiers, lower rates of
clinical improvement have been reported in the past.2 Statistically
signiﬁcant differences were noted between TASC C and D lesions in
terms of primary sustained clinical improvement and primary
patency (76.7% vs. 46.3%, p ¼ 0.03 and 82.1% vs. 44%, p ¼ 0.009).
Interestingly, no statistical differencewas noted between secondary
rates (87.6% vs. 67.3%, p ¼ 0.09 for secondary sustained clinical
improvement and 84.9% vs. 63.9%, p ¼ 0.12 for secondary patency,
respectively). Furthermore, patients with TASC D lesions experi-
enced ISRmore frequently thanpatientswith TASCC lesions (35% vs.
10%, p¼ 0.005). These results suggest that, provided strict follow-upis observed, not only TASC C but also TASC D patients beneﬁt from
this endovascular strategy. In our study, stent thrombosis and
restenosis were the causative factors associated with a lack of
clinical improvement. Thrombosis results from the inﬂuence of
various factors such as cardiac insufﬁciency, hypercoagulability,
pro-inﬂammatory states, severity of initial clinical presentation or
poor runoff,13 whereas ISR is related to intimal hyperplasia. At 1
year, in-stent thrombosis and ISR rates were 11.3% and 19.3% in our
study, compared with 24% and 10% in that of Bosiers.12 Taken
together, these results represent a cumulated rate of events at 1-
year follow-up of 30.6% compared with 34%, respectively. Both
studies are similar regarding the deﬁnition of ISR, which was
considered signiﬁcant by a PSV ratio2.4. However, considering the
long time interval between two successive ultrasound exams in
their follow-up schedule (6months vs. 3months in the STELLA trial),
some ISR events might have been considered as stent thrombosis.
Consequently, we cannot rule out that their stent thrombosis rate
might have been overestimated and their ISR rates underestimated,
which could explain this discrepancy. Nevertheless, the 1-year rate
of ISR seems particularly low (<20%) in both studies considering the
severity of the lesions. This might be related to the sub-intimal
recanalisation technique used to treat occluded lesions. The loo-
ped guide wire tip is crossing the lesion in the sub-intimal space,
hence splitting apart a considerable amount of smooth muscle cells
in the media. This could reduce signiﬁcantly the pool of smooth
muscle cells available to induce intimal hyperplasia compared with
the transluminal technique. We also have noticed that most of the
restenosis events (eight out of 12) have been detected during the
ﬁrst 6 months. This contrasts with the delay of 12 months usually
observed bymost authors14 suggesting that narrow US surveillance
is preferable. In some cases, ISR and thrombosis were left untreated
due to the lack of consecutive symptoms or due to a degradation of
the general condition of patients.
Figure 5. (a) Freedom from target lesion revascularisation. One-year TLR-free cumulative survival rate was 81.1%. (b) Freedom from target extremity revascularisation. One year
TER-free cumulative survival rate was 96.3%. TLR: target lesion revascularisation. TER: target extremity revascularisation.
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rather focussed on the clinical outcome of a speciﬁc subset of
patients requiring challenging endovascular procedures. More-
over, even for longest TASC and D lesions, recent studies haveTable 7
Medical treatment survey.
Baseline 1 mo 3 mo 6 mo 9 mo 12 mo
Antiplatelet agents
0 agent 0 0 0 0 0 0
1 agent 20 11 11 25 32 34
2 agents 38 46 40 23 13 12
Vitamin K antagonists 12 12 8 9 11 11
Statin 41 45 44 42 40 40
Angiotensin-converting
enzyme inhibitors
43 45 42 40 36 37reported a success rate of recanalisation of about 80e85% of
the cases.3
For comparison purposes, after 2 years, the primary patency
rates of venous and polytetraﬂuoroethylene (PTFE) above-the-knee
femoropopliteal bypass are estimated to be 80% and 69%, respec-
tively.14 Patency rates of below-the-knee femoropopliteal bypass
have been reported to be up to 71% at 3 years.15 Patency rates
following sub-intimal angioplasty vary widely between 56% and
70% at 1 year.3 Studies usually do not differentiate between IC and
CLI patients when reporting patency rates. We report a 1-year
primary patency rate of 79.4% in IC patients and 61.4% in CLI
patients with secondary patency rates of 90% and 71%, respectively.
These results compare favourably with other data given the high
proportion of CLI patients in our cohort. Important differences
between primary and secondary rates emphasise the need for
narrow surveillance and repeated TLR when patency is threatened.
Figure 6. X-rays showing different types of stent fractures according to the Jaff et al. Classiﬁcation: type 1 (panel A), type 2 (panel B), type 3 (panel C) and type 4 (panel D) stent
fractures.
Table 8
Clinical impact and management of stent fractures.
Stent fracture Type of fracture ISR Thrombosis Clinical impact Additional
procedure
and outcome
1 2 þ 0 Return to IC TLR asymptomatic
2 2 0 0 0 0
3 1 0 0 0 0
4 2 þ 0 CLI vs. IC at baseline TLR asymptomatic
5 4 þ 0 IC vs. CLI at baseline TLR asymptomatic
6 3 þ 0 Asymptomatic 0
7 3 þ 0 Asymptomatic 0
8 3 0 0 0 0
9 3 0 0 0 0
10 2 0 0 0 0
11 2 0 0 0 0
12 4 0 0 0 0
13 2 0 0 0 0
14 3 0 0 0 0
15 4 0 þ IC vs. CLI at baseline Considered not
improved
16 2 0 0 0 0
0: no event, ISR: in-stent restenosis, IC: intermittent claudication, CLI: critical limb ischaemia, TLR: target lesion revascularisation., þ: presence of in-stent restenosis.
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Stent fracture rate was particularly elevated. Incidence of
stent fracture in the literature ranges from 2% to 65%.16,17 In
77.4% of the cases, stents were placed in the popliteal artery.
Consequently, stenting crossed the Hunter region and the knee
joint, both zones identiﬁed as vascular bending segments sub-
jected to high mechanical axial stress.18e20 This might explain
the high fracture rate. Interestingly, no fracture has been noted
in stent overlap zones (Fig. 6). Implanted stents were of 6- and
7-mm diameters. These diameters allow treatment of the
majority of superﬁcial femoral artery (SFA) lesions. For patients
with small vessel diameter, stents larger than the nominal
vessel diameter could damage the arterial wall. However, the
correlation between the metallic coverage and the risk of ISR is
not established.21
Most importantly, the clinical impact of stent fracture is still
a matter of controversy in the literature. Some suggest that
stent fractures are associated with a higher incidence of ISR,
thrombosis or embolism.16,17,19 Others do not report a signiﬁcant
association between stent fracture and clinical deteriora-
tion.12,22,23 In our hands, despite the high number of fractures
observed, impact on clinical deterioration remained very
limited.Study limitations
The main limitations of this study are the absence of a control
group and the relatively small sample size of patients, both limiting
the statistical signiﬁcance of our conclusions. In about one-third of
the cases, adjunctive procedures were realised to improve outﬂow
or inﬂow. These procedures had an impact on the outcome of the
femoral stenting and, this constitutes a potential bias in the eval-
uation of the clinical improvement. The inclusion of patients in this
study was inﬂuenced by some criteria such as the ability to cross
the target lesion with a guide wire as well as the presence of inﬂow
and outﬂow lesions. Consequently, conclusions of this study did not
apply to these lesions subgroups and, in particular, to the highly
calciﬁed lesions. Indeed, arterial calciﬁcations are particularly
predictive of technical failure due to the inability to cross the lesion
or to re-enter the true lumen.3 However, presence of calciﬁcations
does not seem to inﬂuence primary-assisted patency.24 To evaluate
functional status outcomes, we have used a subjective clinical scale
and we did not use a quality of life questionnaire.
Conclusion
Primary stenting of TASC C and D lesions appears to be safe and
efﬁcient given the high-sustained clinical improvement and the
J.-M. Davaine et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 432e441 441low rate of ISR observed in our study. Endovascular treatment of
such long and severe lesions exposes to high rate of stent fractures,
which should not be a concern given their low clinical impact. Early
narrow clinical and duplex scan follow-up of long stents is
mandatory to detect potential thrombosis and ISR events. Primary
stenting of TASC C and D lesions needs ongoing surveillance and
longer follow-up, given the high rate of CLI.
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